The Resaphene has received the patent grant notice from the US Patent Authority. Now the only tinnitus therapy with proof of efficacy on the market in the two target regions Europe and the US is protected.
This author has yet to write their bio.Meanwhile lets just say that we are proud admin contributed a whooping 18 entries.
Entries by admin
In order to launch the Tinniwell in the USA, Resaphene founded the new national company Resaphene US LLC. The responsible director was Thomas Rauterkus. In his area of responsibility is also the approval procedure with the competent authority US Food and Drug Administration.
Resaphene Suisse AG was informed after the hearing at the European Patent Office about the forthcoming grant of the patent. As a next step, the Board also expects to complete the patent process in the US. In February 2019, management will introduce tinnitus therapy in the US and drive expansion there. A decision whether a […]
Good news for tinnitus patients: The tinnitus therapy device tinniwell is paid by health insurances in Switzerland and Germany. After approval by an expert physician, the tinniwell is already taken over by Helsana and Swica, depending on the tariff of the patients. In Germany, depending on the tariff of the insured person, the full purchase […]
On 21.06.2018, Resaphene Suisse AG completed its IPO on the Vienna Stock Exchange in the Third Market segment. This step was necessary to give institutional investors the opportunity to invest. The reference price was set at 516.50 euros. This completes the process of changing strategy in the area of financing. This was started in the […]
In the future, the group company Resaphene will cooperate with GEHE Pharma Handel in the distribution of the tinnitus therapy device Tinniwell. From August 2018, the Tinniwell will be introduced in the 800 top-selling pharmacies in Germany. In total, GEHE has a network of 7,000 pharmacies that can be reached. This is another step towards […]
In a comparison test of three digital tinnitus therapy systems performed by the health portal web-gesundheit.de, tinniwell was able to beat out the competition of Tinnitracks and Tinnitus Pro. Among other things, the scope of functions, price / performance ratio and service were evaluated. In all relevant areas, tinniwell convinced the testers, also and above all […]
In order to open up the UK, Ireland and, later, the USA markets for the tinnitus therapy device tinniwell, Resaphene UK Ltd. founded in London. In addition, this country-based venture capital and private equity firm will facilitate an investment in the company, as these investments can be written off in a tax-efficient manner.
In the period from October 2016 to July 2017 in the ENT specialist practice of Dr. med. Johannes Ebbers informed all patients with chronically decompensated tinnitus about the “Tinniwell” treatment device and invited to participate in the application observation. All patients underwent an oto-neurological examination using ear microscopy, tone threshold audiometry, videonystagmography, oriented clinical-neurological examination, […]
Resaphene Suisse AG
9325 Roggwil TG
Phone +41 714 500 668
Fax +41 714 500 669
Resaphene Deutschland GmbH
Phone +49 753 158 481 48
Fax +49 753 158 481 62
Resaphene US LLC
8 The Green Suite
Dover, DE 19901
Phone +1 786 600 1462
Contact United Kingdom
Resaphene UK Ltd.
20-22 Wenlock Road
London N1 7GU
Phone +44 20 32 39 68 53